Pharmaceutical Executive
The decision to eradicate pharma rebates and prompt direct discounts for federal beneficiaries could, if passed, upend the market-what are the critical questions for new products?
Dean Erhardt
Advertisement
President and CEO of D2 Solutions, an advisory and technology firm specializing in pharmaceutical commercialization and supply chain strategies. With over 30 years of experience in the healthcare and life sciences industries, Erhardt is a recognized expert in market access, specialty distribution, and the evolving regulatory landscape. Under his leadership, D2 Solutions provides strategic guidance and digital tools that help manufacturers and providers navigate the complexities of product launches, patient access, and operational efficiency.
Articles by Dean Erhardt
![Dean Erhardt[1].jpg](https://cdn.sanity.io/images/0vv8moc6/pharmexec/eb3013cb10f0ac51d7ac205d81f227635a714120-3000x3900.jpg?w=350&fit=crop&auto=format)
Pharmaceutical Executive
A rule to eradicate drug rebates and prompt direct discounts for federal beneficiaries raises challenging questions for drug manufacturers and other stakeholders.
Advertisement
Latest Updated Articles
Proposed Rebates Rule Raises Tough QuestionsJuly 16th 2019
![Dean Erhardt[1].jpg](https://cdn.sanity.io/images/0vv8moc6/pharmexec/eb3013cb10f0ac51d7ac205d81f227635a714120-3000x3900.jpg?w=300&fit=crop&auto=format)
Advertisement
Advertisement
Trending on PharmExec
1
Asembia ASX26: Adjusting Strategies to Adapt to an Uncertain Global Political and Regulatory Market
2
Which Supply Chains are Most Exposed by Disruptions in The Strait of Hormuz?
3
Asembia AXS26 Summit: The Future of High-Cost Specialty Drugs
4
How are US Regulatory Actions Impacting Pricing?
5